Interestingly, the level of AHNAK methylation was negatively correlated with disease severity, with 44.44% methylation in the normal control group, 38.23% in the chronic hepatitis B group, 34.38% in the compensated cirrhosis group, 31.43% in the decompensated cirrhosis group, and the lowest in the liver cancer group, about 27.7%. Here, AHNAK is linked to liver cancer.